ISDA

Entry Detail

PDB ID:

7L5D

Keywords:

HYDROLASE

Title:

The crystal structure of SARS-CoV-2 Main Protease in complex with demethylated analog of masitinib

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2020-12-21

Release Date:

2020-12-30

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.58 Å

R-Value Free:

0.20

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:3C-like proteinase
Chain IDs:A
Chain Length:306
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTD1 Pfam ID:PF05409 EC:2.7.7.48

Ligand Molecules

DMS

GOL

XNJ

Primary Citation

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.

Drayman, N, DeMarco, J.K, Jones, K.A, Azizi, S.A, Froggatt, H.M, Tan, K, Maltseva, N.I, Chen, S, Nicolaescu, V, Dvorkin, S, Furlong, K, Kathayat, R.S, Firpo, M.R, Mastrodomenico, V, Bruce, E.A, Schmidt, M.M, Jedrzejczak, R, Munoz-Alia, M.A, Schuster, B, Nair, V, Han, K.Y, O'Brien, A, Tomatsidou, A, Meyer, B, Vignuzzi, M, Missiakas, D, Botten, J.W, Brooke, C.B, Lee, H, Baker, S.C, Mounce, B.C, Heaton, N.S, Severson, W.E, Palmer, K.E, Dickinson, B.C, Joachimiak, A, Randall, G, Tay, S.Show

Science 373 931 936 (2021)

PMID: 34285133 DOI: 10.1126/science.abg5827

Abstact

There is an urgent need for antiviral agents that treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs against OC43, a human beta coronavirus that causes the common cold, and evaluated the top hits against SARS-CoV-2. Twenty drugs significantly inhibited replication of both viruses in cultured human cells. Eight of these drugs inhibited the activity of the SARS-CoV-2 main protease, 3CLpro, with the most potent being masitinib, an orally bioavailable tyrosine kinase inhibitor. X-ray crystallography and biochemistry show that masitinib acts as a competitive inhibitor of 3CLpro. Mice infected with SARS-CoV-2 and then treated with masitinib showed >200-fold reduction in viral titers in the lungs and nose, as well as reduced lung inflammation. Masitinib was also effective in vitro against all tested variants of concern (B.1.1.7, B.1.351, and P.1).

Legend

Protein

Chemical

Disease

Primary Citation of related structures